WCN26-4579 Urinary Post-Translationally Modified Fetuin-A as Early Therapeutic Response in Diabetes Patients Treated with SGLT2 Inhibitors

Read full text Summarise with VIRAT
Authors: Han-En Wang, Yi-An Hu, Chi-Hsuan Huang, Tzu-Ling Tseng, Chieh-Hua Lu, Min‐Hsiu Chen, Chih‐Chien Sung
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Fetuin-A has been reported to attenuate inflammation and fibrosis in the kidney. Production of post-translational modifications-Fetuin-A (PTM-FetA), an abnormal Fetuin-A, represents the loss of kidney protection in response to stress. Urinary PTM-FetA (uPTM-FetA) has recently been reported as an early biomarker to predict renal function decline in type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide the reno-protection effect to reduce albuminuria, but the longitudinal therapeutic response of SGLT2i on uPTM-FetA in diabetic patients, including those without microalbuminuria, remains unknown.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Acute Kidney Injury Research Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104622–104622
Publication date
25 March 2026
Language
EN